![]() |
Seasoned public company director and senior capital markets executive brings more than 30 years of financial services leadership, corporate governance and strategic advisory experience, includes senior roles at Cantor Fitzgerald, Natixis, ING Barings and Crédit Lyonnais
STUART, Fla., Nov. 17, 2026 /PRNewswire/ — Health In Tech, Inc. (Nasdaq: HIT) ("Health In Tech" or the "Company"), an AI-enabled InsurTech platform company, today announced the appointment of Christina R. Valauri to its Board of Directors as an independent director, effective November 12, 2026. Ms. Valauri will serve as a member of the Audit Committee, the Compensation Committee and the Nominating and Corporate Governance Committee of the Board.
Ms. Valauri brings more than three decades of Wall Street and capital markets analytical, management and leadership experience, having held Managing Director and senior executive positions at prominent global financial institutions, including Cantor Fitzgerald, Natixis, ING Barings and Crédit Lyonnais. Her leadership roles included Global Director of Equity Research at Cantor Fitzgerald and Co-Head of Equity Capital Markets at First Albany where she also served on the firm’s capital market operating committee. Throughout her career, she has led global research organizations, driven strategic business transformation and established regulatory and supervisory frameworks. A recognized healthcare investment research professional, Ms. Valauri was ranked No. 1 in the biomedical and biotechnology sector in The Wall Street Journal’s "Best on the Street" All-Star Analyst Survey.
Sanjay Shrestha, Chief Executive Officer of Health In Tech, commented:
"Christina brings a valuable combination of Wall Street leadership, healthcare industry insight and public company governance experience," said Sanjay Shrestha, Chief Executive Officer of Health In Tech. "She understands how institutional investors evaluate management teams, business models, competitive positioning and the ability to translate innovation into sustainable growth. Her experience advising emerging healthcare companies also brings a practical perspective on commercialization and the organizational capabilities needed to scale. As we expand our AI-enabled marketplace, strengthen our distribution relationships and advance our product portfolio, we believe Christina’s insights will help our Board evaluate strategic opportunities, support disciplined execution and guide the Company toward long-term shareholder value creation."
Throughout her career, Ms. Valauri has led international equity research teams across New York, London, Hong Kong and Toronto, built and managed institutional research organizations and implemented business transformation initiatives. She also brings substantial experience in corporate governance, regulatory oversight and risk management. As a senior research executive and broker-dealer manager, she established regulatory and supervisory frameworks designed to uphold SEC and FINRA requirements and corporate governance best practices.
Ms. Valauri spent more than 16 years as a senior sell-side equity research analyst covering pharmaceutical, biotechnology and medical technology companies in the U.S. and internationally, including at PaineWebber. Her analytical experience encompasses evaluating emerging healthcare technologies, assessing business models and competitive dynamics, and identifying commercial opportunities and investment considerations. This research background, combined with her understanding of institutional investor expectations, provides valuable insight into the opportunities and challenges facing technology-driven healthcare companies.
Ms. Valauri currently serves as an independent director of two other Nasdaq-listed companies, Valion Bio, Inc. (Nasdaq: VBIO) since July 2024 and Precipio, Inc. (Nasdaq: PRPO) since January 2024, bringing additional public company governance experience to our Board. She is also the Founder and CEO of Sagestone Advisory LLC, where she advises emerging companies on business strategy, capital markets positioning and growth initiatives. Additionally, she serves as a Mentor and Guest Lecturer at Weill Cornell Medicine’s BioVenture eLab, where she previously served as Entrepreneur in Residence, supporting the development and commercialization of innovative healthcare technologies.
Ms. Valauri holds an Executive MBA from Cornell University and a Bachelor of Arts in Biology from Reed College. She is also a National Association of Corporate Directors (NACD) Certified Director.
Forward–Looking Statements
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements relating to Health In Tech, Inc.’s ("Health In Tech," "we," "us" or "our") business strategy, product development and innovation, growth prospects, and future operating and financial performance. In some cases, forward-looking statements can be identified by terminology such as "believe," "may," "will," "potentially," "estimate," "continue," "anticipate," "intend," "expect," "could," "would," "project," "plan," "target" or similar expressions that are predictions of or indicate future events or trends and that do not relate solely to historical matters. Forward-looking statements in this press release include, but are not limited to, statements regarding the expected benefits of the Company’s leadership transition; the Company’s strategic priorities, including accelerating organic growth and commercial execution, expanding adoption of its solutions and strengthening distribution and carrier partnerships; the Company’s intention to evaluate and pursue potential acquisitions, strategic investments, partnerships and other business opportunities; and the Company’s ability to create long-term shareholder value.
These forward-looking statements are based on current expectations and beliefs concerning future events and developments and their potential effects on Health In Tech and are subject to numerous known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside of Health In Tech’s control, that could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These factors include, but are not limited to: risks related to the leadership transition, including our ability to successfully integrate new management and retain key personnel; our ability to identify, negotiate, finance, complete and integrate acquisitions or other strategic transactions on favorable terms, or at all; our ability to obtain funding for our operations and to enhance our current systems and expand our service offerings; our ability to regain and maintain compliance with The Nasdaq Stock Market LLC continued listing requirements; the success, cost and timing of our product development activities; our ability to attract and retain key personnel and qualified employees; our ability to attract new customers and to develop new, and enhance existing, products and services; the impact of competition in our industry and innovation by our competitors; risks related to cybersecurity incidents or other network disruptions; risks related to the use of third-party artificial intelligence; our ability to comply with new or modified laws and regulations applicable to our business, including with respect to the insurance services industry and data privacy requirements; our ability to protect our intellectual property rights and maintain and build our brand; the future trading price of our common stock; and other risks and uncertainties described in the "Risk Factors" section of our most recent Annual Report on Form 10-K and our subsequent Quarterly Reports on Form 10-Q and other filings with the U.S. Securities and Exchange Commission.
Any forward-looking statement made in this press release speaks only as of the date of this press release. New risks and uncertainties may emerge from time to time, and it is not possible for Health In Tech to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this press release. Except as required by applicable law, Health In Tech does not undertake, and expressly disclaims, any obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release.
About Health In Tech
Health In Tech, Inc. (Nasdaq: HIT) is an AI-enabled InsurTech platform company, which offers a marketplace that improves processes in the health insurance industry through vertical integration, process simplification, and automation. By removing friction and complexities, we streamline the underwriting, sales and service process for insurance companies, licensed brokers, Managing General Underwriter ("MGUs") and third-party administrators ("TPAs"). Health In Tech’s platform serves as a marketplace for brokers, TPAs, MGUs and carriers to access self-funded health insurance for employers, providing functions including customized self-funded health plans, bindable stop-loss quotes, AI-enabled underwriting, claims administration and reporting integration.
Investor Contact:
Health In Tech Investor Relations
ir@healthintech.com
The information provided in this article was created by Cision PR Newswire, our news partner. The author's opinions and the content shared on this page are their own and may not necessarily represent the perspectives of Thailand Business Directory.
